Xavier Bosch. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh: See more » Antibodies, Antineutrophil Cytoplasmic/immunologyAntibodies, Antineutrophil Cytoplasmic/metabolismAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, Murine-DerivedAutoimmune Diseases/drug therapyAutoimmune Diseases/immunologyDouble-Blind MethodFemaleHumansLupus Erythematosus, Systemic/diagnosisLupus Erythematosus, Systemic/drug therapyLupus Erythematosus, Systemic/immunologyLupus Nephritis/diagnosisLupus Nephritis/drug therapyLupus Nephritis/immunologyLymphocyte DepletionMalePrognosisRandomized Controlled Trials as TopicReference ValuesRisk AssessmentRituximabSeverity of Illness IndexTreatment FailureVasculitis/drug therapyVasculitis/immunology
Substances: See more » Antibodies, Antineutrophil CytoplasmicAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedRituximab
Year: 2010 PMID: 20186231 DOI: 10.1038/nrneph.2010.13
Source DB: PubMed Journal: Nat Rev Nephrol ISSN: 1759-5061 Impact factor: 28.314